

Cancer Australia

Entity resources and planned performance

Cancer Australia

Section 1: Entity overview and resources	270
1.1 Strategic direction statement.....	270
1.2 Entity resource statement.....	271
Section 2: Outcomes and planned performance	274
2.1 Budgeted expenses and performance for Outcome 1	274
Section 3: Budgeted financial statements.....	282
3.1 Budgeted financial statements	282
3.2 Budgeted financial statements tables.....	283

Cancer Australia

Section 1: Entity overview and resources

1.1 Strategic direction statement¹

As the Australian Government’s national cancer control agency, Cancer Australia aims to reduce the impact of cancer, address disparities, and improve outcomes for people affected by cancer. The Australian Government, through Cancer Australia:

- provides national leadership in cancer control
- facilitates evidence-informed approaches with a range of healthcare providers and groups across the continuum of care
- leads the development of sustainable and effective models of cancer care
- oversees a dedicated budget for cancer research, supports clinical trial capacity and strengthens national data capacity
- provides advice on appropriate cancer care.

To achieve its aims in 2026–27, Cancer Australia will use an evidence-based approach and collaboratively engage with stakeholders to:

- lead the implementation of the Australian Cancer Plan to improve outcomes for all Australians affected by cancer
- partner with First Nations leaders to co-design and deliver improved cancer care for First Nations peoples
- translate evidence to inform best practice cancer care
- oversee a dedicated budget for research into cancer
- support industry-independent cancer clinical trials groups
- drive efforts to strengthen national data capacity
- provide evidence-based cancer information to cancer consumers, health professionals and the community.

The role and functions of Cancer Australia are set out in the *Cancer Australia Act 2006*. Cancer Australia is subject to the *Public Service Act 1999* and the *Auditor-General Act 1997*, and is a non-corporate Commonwealth entity under the *Public Governance, Performance and Accountability Act 2013*.

¹ For more information about the strategic direction of Cancer Australia, refer to the current Corporate Plan, available at: www.canceraustralia.gov.au/about-us/accountability-and-reporting/corporate-plan

1.2 Entity resource statement

Table 1.1 shows the total resourcing from all sources available to the entity for its operations and to deliver programs and services on behalf of the Government.

The table summarises how resources will be applied by outcome (government strategic policy objectives) and by administered (on behalf of the Government or the public) and departmental (for the entity's operations) classification.

For more detailed information on special accounts and special appropriations, please refer to the *Budget Paper No. 4 – Agency Resourcing*.

Information in this table is presented on a resourcing (that is, appropriations/cash available) basis, whilst the 'Budgeted expenses by Outcome 1' tables in Section 2 and the financial statements in Section 3 are presented on an accrual basis. Amounts presented below are consistent with amounts presented in the Appropriation Bills themselves.

Table 1.1: Cancer Australia resource statement – Budget estimates for 2026–27 as at Budget May 2026

	2025–26 Estimated actual \$'000	2026–27 Estimate \$'000
DEPARTMENTAL		
Prior year appropriation available	4,213	3,516
Annual appropriations		
Ordinary annual services ^(a)		
Departmental appropriation	13,223	13,582
s74 retained revenue receipts ^(b)	3,466	2,067
Departmental Capital Budget ^(c)	85	86
Other services ^(d)		
Equity injection	-	-
Total departmental annual appropriations	16,774	15,735
Total departmental resourcing	20,987	19,251
ADMINISTERED		
Prior year appropriation available	4,936	4,936
Annual appropriations		
Ordinary annual services ^(a)		
Outcome 1	34,379	34,633
Other services ^(d)		
Administered assets and liabilities	-	-
Total administered annual appropriations	34,379	34,633
Total administered resourcing	39,315	39,569
Total resourcing for Cancer Australia	60,302	58,820
	2025–26	2026–27
Average staffing level (number)	75	75

All figures are GST exclusive.

^(a) Appropriation Bill (No. 1) 2026–2027.

^(b) Estimated retained revenue receipts under section 74 of the *Public Governance, Performance and Accountability Act 2013* (PGPA Act).

^(c) Departmental Capital Budgets are not separately identified in Appropriation Bill (No. 1) and form part of ordinary annual services items. Please refer to Table 3.5 within this chapter for further details. For accounting purposes, this amount has been designated as a 'contribution by owner'.

^(d) Appropriation Bill (No. 2) 2026–2027.

1.3 Budget measures

Budget measures in Part 1 relating to Cancer Australia are detailed in the Budget Paper No. 2 and are summarised below.

Table 1.2: Cancer Australia 2026–27 Budget measures

Part 1: Measures announced since the 2025–26 Mid-Year Economic and Fiscal Outlook (MYEFO)

Program	2025–26 \$'000	2026–27 \$'000	2027–28 \$'000	2028–29 \$'000	2029–30 \$'000
Reducing Spending on Consultants, Contractors and Labour Hire, and Non-wages Expenses - one year extension^(a)					
Cancer Australia	1.1				
Departmental payments	-	-	-	-	(193)
Total payments	-	-	-	-	(193)

Prepared on a Government Financial Statistics (Underlying Cash) basis. Figures displayed as a negative (-) represent a decrease in funds and a positive (+) represent an increase in funds.

^(a) Cancer Australia is not the lead entity for this measure. Cancer Australia impacts only are shown in this table.

Section 2: Outcomes and planned performance

Government outcomes are the intended results, impacts or consequences of actions by the Government on the Australian community. Commonwealth programs are the primary vehicle by which government entities achieve the intended results of their outcome statements. Entities are required to identify the programs which contribute to government outcomes over the Budget and forward years.

Each outcome is described below together with its related programs. The following provides detailed information on expenses for each outcome and program, further broken down by funding source.

Note:

Performance reporting requirements in the Portfolio Budget Statements are part of the Commonwealth performance framework established by the *Public Governance, Performance and Accountability Act 2013*. It is anticipated that the performance measure described in Portfolio Budget Statements will be read with broader information provided in an entity's corporate plans and annual performance statements – included in Annual Reports – to provide a complete picture of an entity's planned and actual performance.

The most recent Corporate Plan for Cancer Australia can be found at:
www.canceraustralia.gov.au/about-us/accountability-and-reporting/corporate-plan

The most recent Annual Performance Statements can be found at:
www.canceraustralia.gov.au/about-us/accountability-and-reporting/annual-reports

2.1 Budgeted expenses and performance for Outcome 1

Outcome 1

Minimised impacts of cancer, including through national leadership in cancer control with targeted research and clinical trials; evidence informed clinical practice; strengthened national data capacity; community and consumer information and support.

Program contributing to Outcome 1

Program 1.1: Improved Cancer Control

Linked Programs

Other Commonwealth entities that contribute to Outcome 1
Department of Health, Disability and Ageing
<p>Program 1.1: Health Research, Coordination and Access</p> <p>The Department of Health, Disability and Ageing has responsibility for health and medical research through the Medical Research Future Fund, which will support the sustainability of the health system into the future and drive further medical innovation.</p> <p>Program 1.5: Preventive Health and Chronic Disease Support</p> <p>The Department of Health, Disability and Ageing has policy responsibility for improving the detection, treatment and survival outcomes for people with cancer. This includes oversight of cancer screening programs, such as the National Bowel Cancer Screening Program, the National Lung Screening Program, the BreastScreen Australia Program and the National Cervical Screening Program.</p>

Budgeted expenses for Outcome 1

This table shows how much the entity intends to spend (on an accrual basis) on achieving the outcome, broken down by program, as well as by Administered and Departmental funding sources.

Table 2.1.1: Budgeted expenses for Outcome 1

Outcome 1: Minimised impacts of cancer, including through national leadership in cancer control with targeted research and clinical trials; evidence informed clinical practice; strengthened national data capacity; community and consumer information and support.

	2025–26 Estimated actual \$'000	2026–27 Budget \$'000	2027–28 Forward estimate \$'000	2028–29 Forward estimate \$'000	2029–30 Forward estimate \$'000
Program 1.1: Improved Cancer Control					
Administered expenses					
Ordinary annual services ^(a)	34,379	34,633	23,876	23,614	24,130
Departmental expenses					
Departmental appropriation ^(b)	16,689	15,649	12,317	12,477	12,589
Expenses not requiring appropriation in the Budget year ^(c)	210	206	276	218	206
Operating deficit (surplus)	500	-	-	-	-
Total for Program 1.1	51,778	50,488	36,469	36,309	36,925
Total expenses for Outcome 1	51,778	50,488	36,469	36,309	36,925
	2025–26	2026–27			
Average staffing level (number)	75	75			

^(a) Appropriation Bill (No. 1) 2026–2027.

^(b) Departmental appropriation combines 'Ordinary annual services Appropriation Bill (No. 1)' and 'Revenue from independent sources (s74)'.

^(c) Expenses not requiring appropriation in the Budget year are made up of depreciation expense, amortisation expense, makegood expenses and audit fees, interest on RoU (Right-of-Use asset) and credit applied to rental supplier expenses (rental payments).

Performance measures for Outcome 1

Table 2.1.2 details the performance measures for each program associated with Outcome 1. It is used by entities to describe the results they plan to achieve and the related key activities, as detailed in the current corporate plan, the context in which these activities are delivered, and how the performance of these activities will be measured. Where relevant, details of the 2026–27 Budget measures that have created new programs or materially changed existing programs are provided.

Table 2.1.2: Performance measures for Outcome 1

Outcome 1	
Minimised impacts of cancer, including through national leadership in cancer control with targeted research and clinical trials; evidence informed clinical practice; strengthened national data capacity; community and consumer information and support.	
Program 1.1: Improved Cancer Control	
Provide national leadership in cancer control across the care continuum to reduce the impact of cancer, address disparities, and improve outcomes for people affected by cancer through the development and promotion of evidence-based practice, funding cancer research, and providing consumers and health professionals with cancer information and resources.	
Key Activities	<ul style="list-style-type: none"> • Provide national leadership in cancer control. • Develop and promote evidence-based best practice cancer care. • Fund cancer research and drive efforts to strengthen national data capacity in consultation with relevant agencies. • Provide consumer and health professional cancer information and resources.

Program 1.1: Improved Cancer Control		
Year	Performance Measure	Expected Performance Results
Current Year 2025–26	<p>Evaluation of the sector’s progress towards the Australian Cancer Plan’s 2-year actions.</p> <p>Progress activities to achieve priority 5-year actions in the Plan (2026–28).</p>	<p>Undertake evaluation of the sector’s progress [including the Commonwealth, States and Territories and cancer control stakeholders] of delivering on the Plan’s 2-year actions (2025–26).</p> <p>Review and progress activities to achieve priority 5-year actions in the Plan.</p> <p>Complete and Publish the National Cancer Data Framework.</p> <p>Target: On track</p>
Year	Performance Measure	Planned Performance Results
Budget Year 2026–27	Monitoring and evaluation of the sector’s progress towards the Australian Cancer Plan’s 5-year actions.	<p>Assessment of potential gaps and required responses in implementation of the Plan as needed.</p> <p>Evaluate progress towards 5-year actions and update as needed.</p> <p>Define to deliver 10-year ambitions.</p>
Forward Estimates 2027–30	As per 2026–27	As per 2026–27

Program 1.1: Improved Cancer Control		
Year	Performance Measure	Expected Performance Results
Current Year 2025–26	Support the Department of Health, Disability and Ageing in ongoing implementation activities for the NLCSP.	<p>Deliver program-specific research activities.</p> <p>Target: On track</p>
Year	Performance Measure	Planned Performance Results
Budget Year 2026–27	Support the Department of Health, Disability and Ageing in ongoing implementation activities for the NLCSP.	Deliver program-specific research activities.
Forward Estimates 2027–30	As per 2026–27	As per 2026–27

Program 1.1: Improved Cancer Control		
Year	Performance Measure	Expected Performance Results
Current Year 2025–26	<ol style="list-style-type: none"> 1. Work with First Nations leaders to co-design and deliver improved cancer care for First Nations people aligned with the priorities of the Australian Cancer Plan. 2. Improving First Nations Cancer Outcomes: Lead delivery of activities to ensure mainstream health services are culturally safe and accessible: <ul style="list-style-type: none"> - Partnerships for Culturally Safe Cancer Care grant program to improve cultural safety in cancer services. - First Nations Cancer Scholarships to increase Aboriginal and Torres Strait Islander participation in research, health and public policy. - Partnerships for Cancer Research grants program to build the capacity of the Indigenous cancer research sector. 	<ol style="list-style-type: none"> 1. First Nations cancer control initiatives led and co-designed by First Nations partners that align with the priorities of the Australian Cancer Plan and complement the strategic objectives of the Aboriginal and Torres Strait Islander Cancer Plan. 2. Deliver and commence ongoing evaluation for each initiative: <ul style="list-style-type: none"> - Partnerships for Culturally Safe Cancer Care grants. - First Nations Cancer Scholarships. - Partnerships for Cancer Research grants. <p>Target: On track</p>
Year	Performance Measure	Planned Performance Results
Budget Year 2026–27	<ol style="list-style-type: none"> 1. Work with First Nations leaders to co-design and deliver improved cancer care for First Nations people aligned with the priorities of the Australian Cancer Plan. 2. Improving First Nations Cancer Outcomes: Lead delivery of activities to ensure mainstream health services are culturally safe and accessible: <ul style="list-style-type: none"> - Partnerships for Culturally Safe Cancer Care grant program to improve cultural safety in cancer services. - First Nations Cancer Scholarships to increase Aboriginal and Torres Strait Islander participation in research, health and public policy. - Partnerships for Cancer Research grants program to build the capacity of the Indigenous cancer research sector. 	<ol style="list-style-type: none"> 1. First Nations cancer control initiatives led and co-designed by First Nations partners that align with the priorities of the Australian Cancer Plan and complement the strategic objectives of the Aboriginal and Torres Strait Islander Cancer Plan. 2. Deliver and commence ongoing evaluation for each initiative: <ul style="list-style-type: none"> - Partnerships for Culturally Safe Cancer Care grants. - First Nations Cancer Scholarships. - Partnerships for Cancer Research grants.
Forward Estimates 2027–30	<ol style="list-style-type: none"> 1. Funding for the Improving First Nations Cancer Outcomes budget measure concludes in June 2027 with no continuous Performance Measures. 	<ol style="list-style-type: none"> 1. Funding for the Improving First Nations Cancer Outcomes budget measure concludes in June 2027 with no continuous Planned Performance Results.

Program 1.1: Improved Cancer Control		
Year	Performance Measure	Expected Performance Results
Current Year 2025–26	Maintain currency of statistical and tumour-specific information on Cancer Australia’s website: www.canceraustralia.gov.au	Up to date evidence-based cancer information available on the Cancer Australia website. ≥5 cancer information topics reviewed and updated. Target: On track
Year	Performance Measure	Planned Performance Results
Budget Year 2026–27	Maintain currency of statistical and tumour-specific information on Cancer Australia’s website: www.canceraustralia.gov.au	Up to date evidence-based cancer information available on the Cancer Australia website. ≥5 cancer information topics reviewed and updated.
Forward Estimates 2027–30	As per 2026–27	As per 2026–27

Program 1.1: Improved Cancer Control		
Year	Performance Measure	Expected Performance Results
Current Year 2025–26	Analyse, interpret and translate evidence to inform best practice cancer care.	Translate research into evidence-based information to assist and inform cancer care policy. Target: On track
Year	Performance Measure	Planned Performance Results
Budget Year 2026–27	Analyse, interpret and translate evidence to inform best practice cancer care.	Translate research into evidence-based information to assist and inform cancer care policy.
Forward Estimates 2027–30	As per 2026–27	As per 2026–27

Program 1.1: Improved Cancer Control		
Year	Performance Measure	Expected Performance Results
Current Year 2025–26	Implement and administer priority-driven research investment annually.	Deliver at least one annual grant round to fund priority-driven research investment. Target: On track
Year	Performance Measure	Planned Performance Results
Budget Year 2026–27	Implement and administer priority-driven research investment annually.	Deliver at least one annual grant round to fund priority-driven research investment.
Forward Estimates 2027–30	As per 2026–27	As per 2026–27

Program 1.1: Improved Cancer Control		
Year	Performance Measure	Expected Performance Results
Current Year 2025–26	Maintain currency of data published on the National Cancer Control Indicators (NCCI) website.	Maintain published data analyses and insights on the National Cancer Control Indicators website. Target: On track
Year	Performance Measure	Planned Performance Results
Budget Year 2026–27	Maintain currency of data published on the National Cancer Control Indicators (NCCI) website.	Maintain published data analyses and insights on the National Cancer Control Indicators website.
Forward Estimates 2027–30	As per 2026–27	As per 2026–27
Material changes to Program 1.1 resulting from 2026–27 Budget Measures: Nil		

Section 3: Budgeted financial statements

Section 3 presents budgeted financial statements which provide a comprehensive snapshot of entity finances for the 2026–27 Budget year, including the impact of budget measures and resourcing on financial statements.

3.1 Budgeted financial statements

3.1.1 Differences between entity resourcing and financial statements

This section is not applicable to Cancer Australia.

3.1.2 Explanatory notes and analysis of budgeted financial statements

Departmental Resources

Comprehensive Income Statement

This statement details budgeted financial results for Cancer Australia in 2026–27.

A break-even position is anticipated for 2026–27 and the forward years.

Budget measures affecting the departmental appropriations are provided in Table 1.2.

Balance Sheet

Assets and liabilities, excluding Land and Buildings and lease liabilities, are anticipated to remain relatively stable across the forward years. There is an anticipated decrease in Land and Buildings and lease liabilities over the forward estimates.

Cash Flow

Cash flows are consistent with income, expenses, and asset movements.

Administered Resources

Administered funding for Cancer Australia programs will continue in 2026–27. The level of administered funding across forward years represents Government expenditure on programs delivered to all Australians through Cancer Australia.

3.2 Budgeted financial statements tables

Table 3.1: Comprehensive income statement (showing net cost of services) for the period ended 30 June

	2025–26 Estimated actual \$'000	2026–27 Budget \$'000	2027–28 Forward estimate \$'000	2028–29 Forward estimate \$'000	2029–30 Forward estimate \$'000
EXPENSES					
Employee benefits	11,169	11,417	10,729	11,291	11,374
Supplier expenses	3,557	1,696	1,408	1,247	1,276
Grants expenses	1,584	1,618	-	-	-
Depreciation and amortisation	1,068	1,112	456	157	145
Interest on RoU	17	8	-	-	-
Other expenses	4	4	-	-	-
Total expenses	17,399	15,855	12,593	12,695	12,795
LESS:					
OWN-SOURCE INCOME					
Revenue					
Other revenue	3,466	2,067	-	-	-
Total revenue	3,466	2,067	-	-	-
Gains					
Other	61	61	61	61	61
Total gains	61	61	61	61	61
Total own-source income	3,527	2,128	61	61	61
Net cost of (contribution by) services	13,872	13,727	12,532	12,634	12,734
Revenue from Government	13,223	13,582	12,317	12,477	12,589
Surplus (deficit)	(649)	(145)	(215)	(157)	(145)
Surplus (deficit) attributable to the Australian Government	(649)	(145)	(215)	(157)	(145)
OTHER COMPREHENSIVE INCOME					
Changes in asset revaluation reserves	-	-	-	-	-
Total other comprehensive income	-	-	-	-	-
Total comprehensive income (loss) attributable to the Australian Government	(649)	(145)	(215)	(157)	(145)

Table 3.1: Comprehensive income statement (showing net cost of services) for the period ended 30 June (continued)

Note: Impact of net cash appropriation arrangements

	2025–26 Estimated actual \$'000	2026–27 Budget \$'000	2027–28 Forward estimate \$'000	2028–29 Forward estimate \$'000	2029–30 Forward estimate \$'000
Total comprehensive income (loss) attributable to the Australian Government	(649)	(145)	(215)	(157)	(145)
plus: non-appropriated expenses depreciation/amortisation expenses	332	376	226	157	145
plus: depreciation/amortisation expenses for RoU assets	736	736	230	-	-
less: lease principal repayments	(919)	(967)	(241)	-	-
Total comprehensive income (loss) attributable to the agency	(500)	-	-	-	-

Prepared on Australian Accounting Standards basis.

RoU = Right-of-Use asset.

Table 3.2: Budgeted departmental balance sheet (as at 30 June)

	2025–26 Estimated actual \$'000	2026–27 Budget \$'000	2027–28 Forward estimate \$'000	2028–29 Forward estimate \$'000	2029–30 Forward estimate \$'000
ASSETS					
Financial assets					
Cash and cash equivalents	125	125	125	125	125
Receivables	3,590	3,585	3,579	3,379	3,374
Total financial assets	3,715	3,710	3,704	3,504	3,499
Non-financial assets					
Property, plant and equipment	128	94	67	178	132
Land and buildings	1,321	336	-	-	-
Intangibles	6	4	4	24	19
Other	169	169	169	169	169
Total non-financial assets	1,624	603	240	371	320
Total assets	5,339	4,313	3,944	3,875	3,819
LIABILITIES					
Payables					
Suppliers	584	580	580	580	580
Other payables	24	24	24	24	24
Total payables	608	604	604	604	604
Interest bearing liabilities					
Leases	1,208	241	-	-	-
Total interest bearing liabilities	1,208	241	-	-	-
Provisions					
Employees	2,766	2,766	2,766	2,766	2,766
Other provisions	281	285	285	285	285
Total provisions	3,047	3,051	3,051	3,051	3,051
Total liabilities	4,863	3,896	3,655	3,655	3,655
Net assets	476	417	289	220	164
EQUITY					
Contributed equity	1,895	1,981	2,068	2,156	2,245
Reserves	103	103	103	103	103
Retained surpluses or (accumulated deficits)	(1,522)	(1,667)	(1,882)	(2,039)	(2,184)
Total equity	476	417	289	220	164

Prepared on Australian Accounting Standards basis.

**Table 3.3: Departmental statement of changes in equity – summary of movement
(Budget year 2026–27)**

	Retained earnings	Asset revaluation reserve	Contributed equity/ capital	Total equity
	\$'000	\$'000	\$'000	\$'000
Opening balance as at 1 July 2026				
Balance carried forward from previous period	(1,522)	103	1,895	476
Surplus (deficit) for the period	(145)	-	-	(145)
Capital budget - Bill 1 (DCB)	-	-	86	86
Estimated closing balance as at 30 June 2027	(1,667)	103	1,981	417

Prepared on Australian Accounting Standards basis.

DCB = Departmental Capital Budget

Table 3.4: Budgeted departmental statement of cash flows (for the period ended 30 June)

	2025–26 Estimated actual \$'000	2026–27 Budget \$'000	2027–28 Forward estimate \$'000	2028–29 Forward estimate \$'000	2029–30 Forward estimate \$'000
OPERATING ACTIVITIES					
Cash received					
Appropriations	13,920	13,587	12,323	12,677	12,594
Sale of goods and rendering of services	3,466	2,067	-	-	-
Net GST received	186	186	186	186	97
Other cash received	-	-	-	-	-
Total cash received	17,572	15,840	12,509	12,863	12,691
Cash used					
Employees	11,169	11,417	10,729	11,291	11,374
Suppliers	3,500	1,639	1,347	1,186	1,215
Interest payments on lease liability	17	8	-	-	-
Grants	1,584	1,618	-	-	-
Net GST paid	186	186	186	186	97
Section 74 receipts transferred to the OPA	-	-	-	-	-
Total cash used	16,456	14,868	12,262	12,663	12,686
Net cash from (or used by) operating activities	1,116	972	247	200	5
INVESTING ACTIVITIES					
Cash used					
Purchase of property, plant and equipment and intangibles	282	91	93	288	94
Total cash used	282	91	93	288	94
Net cash from (or used by) investing activities	(282)	(91)	(93)	(288)	(94)
FINANCING ACTIVITIES					
Cash received					
Capital budget - Bill 1 (DCB)	85	86	87	88	89
Total cash received	85	86	87	88	89
Cash used					
Lease principal repayments	919	967	241	-	-
Total cash used	919	967	241	-	-
Net cash from (or used by) financing activities	(834)	(881)	(154)	88	89
Net increase (or decrease) in cash held	-	-	-	-	-
Cash and cash equivalents at the beginning of the reporting period	125	125	125	125	125
Cash and cash equivalents at the end of the reporting period	125	125	125	125	125

Prepared on Australian Accounting Standards basis.

DCB = Departmental Capital Budget
OPA = Official Public Account

Table 3.5: Departmental capital budget statement (for the period ended 30 June)

	2025–26 Estimated actual \$'000	2026–27 Budget \$'000	2027–28 Forward estimate \$'000	2028–29 Forward estimate \$'000	2029–30 Forward estimate \$'000
CAPITAL APPROPRIATIONS					
Capital budget - Bill 1 (DCB)	85	86	87	88	89
Total capital appropriations	85	86	87	88	89
Total new capital appropriations represented by:					
Purchase of non-financial assets	85	86	87	88	89
Total represented by	85	86	87	88	89
PURCHASE OF NON-FINANCIAL ASSETS					
Funded by capital appropriation - DCB ^(a)	85	86	87	88	89
Funded internally from departmental resources	197	5	6	200	5
Total acquisitions of non-financial assets	282	91	93	288	94
RECONCILIATION OF CASH USED TO ACQUIRE ASSETS TO ASSET MOVEMENT TABLE					
Total purchases	282	91	93	288	94
Total cash used to acquire assets	282	91	93	288	94

Prepared on Australian Accounting Standards basis.

DCB = Departmental Capital Budget

^(a) Does not include annual finance lease costs. Includes purchases from current and previous years' DCB.

Table 3.6: Statement of departmental asset movements (Budget year 2026–27)

	Buildings	Property, plant and equipment	Intangibles	Total
	\$'000	\$'000	\$'000	\$'000
As at 1 July 2026				
Gross book value	1,389	2,205	1,349	4,943
Gross book value - RoU	4,874	-	-	4,874
Accumulated depreciation/amortisation and impairment	(1,034)	(2,077)	(1,343)	(4,454)
Accumulated depreciation/amortisation and impairment - RoU	(3,908)	-	-	(3,908)
Opening net book balance	1,321	128	6	1,455
CAPITAL ASSET ADDITIONS				
Estimated expenditure on new or replacement assets				
Funded by capital appropriation - - DCB ^(a)	-	86	-	86
Funded internally from departmental resources	-	-	5	5
By purchase - RoU	-	-	-	-
Total additions	-	86	5	91
Other movements				
Depreciation/amortisation expense	(249)	(120)	(7)	(376)
Depreciation/amortisation expense - RoU	(736)	-	-	(736)
Total other movements	(985)	(120)	(7)	(1,112)
As at 30 June 2027				
Gross book value	1,389	2,291	1,354	5,034
Gross book value - RoU	4,874	-	-	4,874
Accumulated depreciation amortisation and impairment	(1,283)	(2,197)	(1,350)	(4,830)
Accumulated depreciation/amortisation and impairment - RoU	(4,644)	-	-	(4,644)
Closing net book balance	336	94	4	434

Prepared on Australian Accounting Standards basis.

DCB = Departmental Capital Budget

RoU = Right-of-Use asset

^(a) Does not include annual finance lease costs. Includes purchases from current and previous years' DCB.

Table 3.7: Schedule of budgeted income and expenses administered on behalf of Government (for the period ended 30 June)

	2025–26 Estimated actual \$'000	2026–27 Budget \$'000	2027–28 Forward estimate \$'000	2028–29 Forward estimate \$'000	2029–30 Forward estimate \$'000
EXPENSES ADMINISTERED ON BEHALF OF GOVERNMENT					
Grants	24,355	24,235	16,860	16,308	16,942
Suppliers	10,024	10,398	7,016	7,306	7,188
Total expenses administered on behalf of Government	34,379	34,633	23,876	23,614	24,130
INCOME ADMINISTERED ON BEHALF OF GOVERNMENT					
Revenue					
Non-taxation					
Other non-tax revenue	-	-	-	-	-
Total non-taxation revenue	-	-	-	-	-
Total revenues administered on behalf of Government	-	-	-	-	-
Total income administered on behalf of Government	-	-	-	-	-

Prepared on Australian Accounting Standards basis.

Table 3.8: Schedule of budgeted assets and liabilities administered on behalf of Government (as at 30 June)

	2025–26 Estimated actual \$'000	2026–27 Budget \$'000	2027–28 Forward estimate \$'000	2028–29 Forward estimate \$'000	2029–30 Forward estimate \$'000
ASSETS ADMINISTERED ON BEHALF OF GOVERNMENT					
Financial assets					
Cash and cash equivalents	34	34	34	34	34
Receivables	1,524	1,524	1,524	1,524	1,524
Total financial assets	1,558	1,558	1,558	1,558	1,558
Non financial assets					
Prepayments	252	252	252	252	252
Total financial assets	252	252	252	252	252
Total assets administered on behalf of Government	1,810	1,810	1,810	1,810	1,810
LIABILITIES ADMINISTERED ON BEHALF OF GOVERNMENT					
Payables					
Suppliers	2,085	2,085	2,085	2,085	2,085
Grants	3,011	3,011	3,011	3,011	3,011
Total payables	5,096	5,096	5,096	5,096	5,096
Total liabilities administered on behalf of Government	5,096	5,096	5,096	5,096	5,096

Prepared on Australian Accounting Standards basis.

Table 3.9: Schedule of budgeted administered cash flows (for the period ended 30 June)

	2025–26 Estimated actual \$'000	2026–27 Budget \$'000	2027–28 Forward estimate \$'000	2028–29 Forward estimate \$'000	2029–30 Forward estimate \$'000
OPERATING ACTIVITIES					
Cash received					
Net GST received	624	624	624	624	-
Other	-	-	-	-	-
Total cash received	624	624	624	624	-
Cash used					
Grant payments	24,447	24,327	16,952	16,400	16,942
Suppliers	10,556	10,930	7,548	7,838	7,188
Total cash used	35,003	35,257	24,500	24,238	24,130
Net cash from (or used by) operating activities	(34,379)	(34,633)	(23,876)	(23,614)	(24,130)
Net increase (or decrease) in cash held	(34,379)	(34,633)	(23,876)	(23,614)	(24,130)
Cash at beginning of reporting period	34	34	34	34	34
Cash from the OPA for:					
- appropriations	34,379	34,633	23,876	23,614	24,130
- GST	624	624	624	624	-
Cash to the OPA					
- return of GST	(624)	(624)	(624)	(624)	-
- other	-	-	-	-	-
Cash at end of reporting period	34	34	34	34	34

Prepared on Australian Accounting Standards basis.

OPA = Official Public Account